Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) - Epidemiology Forecast to 2030

Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) - Epidemiology Forecast to 2030

  • January 2021 •
  • 80 pages •
  • Report ID: 6010469 •
  • Format: PDF
‘Familial Hypercholesterolemia (FH) - Epidemiology Forecast–2030’ report delivers an in-depth understanding of the disease, historical and forecasted Familial Hypercholesterolemia (FH) epidemiology in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Familial Hypercholesterolemia (FH) Understanding
Familial Hypercholesterolemia (FH) is a genetic and hereditary disorder, which leads to a high level of LDL (bad) cholesterol. The condition begins at birth and can cause heart attacks at an early age.
FH is an autosomal-dominant disorder associated with mutations in the LDL receptor gene resulting in elevated plasma low-density lipoprotein cholesterol levels and premature atherosclerotic cardiovascular disease (ASCVD). FH is significantly under-recognized with as many as 1 in 300 having the heterozygous form and one in a million having the homozygous form of the disease. Patients with FH are characterized by a decreased clearance of LDL from the circulation and an increase in LDL synthesis, with changes in homozygotes being more marked than in heterozygotes, consistent with a gene dosage effect.
Heterozygous FH (HeFH) (mutation in one allele) is related with plasma LDL-C levels >190 mg/dL, whereas homozygous FH (HoFH) (mutation in both alleles) is associated with plasma LDL-C levels >500 mg/dL. As a result, there is a 20-fold increase in the risk of premature coronary heart disease (CHD) in untreated patients compared to control. HeFH patients usually develop CHD, without treatment, before age 55 and 60 for men and women, respectively. HoFH patients, however, develop CHD very early in life and can die before age 20 if untreated.

Familial Hypercholesterolemia (FH) Epidemiology Perspective
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Prevalent Population of Familial hypercholesterolemia, Diagnosed Prevalent Population of Familial hypercholesterolemia, Age-specific Distribution of Familial Hypercholesterolemia and Mutation-specific Diagnosed Prevalence of Familial Hypercholesterolemia in the 7MM market covering the United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom) and Japan from 2017 to 2030.

Familial Hypercholesterolemia (FH) Detailed Epidemiology Segmentation
• The total prevalent population of Familial Hypercholesterolemia (FH) in the seven major markets is estimated to be 3,113,189 in 2020. However, total diagnosed prevalent patient population of Familial Hypercholesterolemia (FH) is estimated to be 598,635 in 2020, which is anticipated to increase by 2030 in the seven major markets.
• The diagnosed prevalence of FH is estimated to be 323,808 in the United States in 2020.
• The diagnosed prevalent cases of HoFH and HeFH in the United States were 652 and 289,693 in 2017.
• In the US, in 2017, FH was most prevalent in the age group of 50-59 years, followed by 60-69 years, with 75,780 and 69,683 cases.
• In the US, the estimated number of mutation-specific cases of FH caused by LDL receptor, APO B, PCSK9, and other rare mutations (SREBP2, STAP1, LDLRAP1 genes) were 251,148, 14,517, 13,065, and 11,613 cases in 2017.
• In the EU5 Countries, France had the maximum diagnosed prevalent population of Familial Hypercholesterolemia (FH) in 2017, followed by the United Kingdom .
• Japan accounts for 54,452 cases of diagnosed prevalent population Familial Hypercholesterolemia (FH) in 2020.

Scope of the Report
• The report covers the descriptive overview of Familial Hypercholesterolemia (FH), explaining its causes, signs and symptoms, pathophysiology.
• The report provides insight into the 7MM historical and forecasted patient pool covering the United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom) and Japan.
• The report assesses the disease risk and burden and highlights the unmet needs of Familial Hypercholesterolemia (FH).
• The report provides the segmentation of the disease epidemiology for 7MM by Total Prevalent Cases of Familial Hypercholesterolemia (FH), Total Diagnosed and Treated Cases of Familial Hypercholesterolemia (FH).

Report Highlights
• Eleven Year Forecast of Familial Hypercholesterolemia (FH)
• 7MM Coverage
• Diagnosed Prevalent Population of Familial Hypercholesterolemia (FH)
• Deleveinsight has segregated prevalence of FH on the basis of genetic types, i.e., homozygous familial hypercholesterolemia (HoFH) and heterozygous hypercholesterolemia (HeFH).
• Report also covers Mutation-specific diagnosed prevalence of FH, including several mutations such as LDL receptor (LDLR) Mutations, Proprotein Convertase Subtilin/Kexin 9 (PCSK9), Apolipoprotein B (Apo B) and Other rare mutations (SREBP2, and STAP1 genes, LDLRAP1 gene).
• The analyst has analysed age-specific epidemiology of FH and segregated the entire FH patient poplation into certain age groups, namely, <18, 18–29, 30–39, 40–49, 50–59, 60–69, 70+. Among these age groups, FH was most prevalent in the age group of 50–59 years, followed by 60¬–69 years

Key Questions Answered
• What is the disease risk, burden and unmet needs of Familial Hypercholesterolemia (FH)?
• What is the historical Familial Hypercholesterolemia (FH) patient pool in the United States, EU5 (Germany, France, Italy, Spain, and the UK) and Japan?
• What would be the forecasted patient pool of Familial Hypercholesterolemia (FH) at the 7MM level?
• What will be the growth opportunities across the 7MM with respect to the patient population pertaining to Familial Hypercholesterolemia (FH)?
• Out of the above-mentioned countries, which country would have the highest prevalent population of Familial Hypercholesterolemia (FH) during the forecast period (2020–2030)?
• At what CAGR the population is expected to grow across the 7MM during the forecast period (2020–2030)?

Reasons to buy
The Familial Hypercholesterolemia (FH) report will allow the user to -
• Develop business strategies by understanding the trends shaping and driving the 7MM Familial Hypercholesterolemia (FH) market.
• Quantify patient share distribution in the 7MM for Familial Hypercholesterolemia (FH).
• The Familial Hypercholesterolemia (FH) epidemiology report and model were written and developed by Masters and Ph.D. level epidemiologists.
• The Familial Hypercholesterolemia (FH) epidemiology model developed is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over the eleven-year forecast period using reputable sources.

Key Assessments
• Patient Segmentation
• Disease Risk and Burden
• Risk of disease by the segmentation
• Factors driving growth in a specific patient population

Geographies Covered
• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan
Study Period: 2017–2030